Dan Pollyea, MD, MS, on the Discovery and Incidence of IDH1 and IDH2 mutations in Patients With AML

Video
Conference|ASH Annual Meeting & Exposition: Leukemia

IDH1/2 mutations have been detected in nearly 20% of patients with acute myeloid leukemia.

A study of venetoclax (Venclexta) plus azacitidine (Vidaza) resulted in higher response rates, longer duration of response, and a higher median overall survival versus azacitidine alone for patients with acute myeloid leukemia (AML) harboring IDH1/2 mutations who were treatment naïve and ineligible for chemotherapy.

The results of the study, which pooled data from an ongoing phase 3 study (NCT02993523) and a phase 1b study (NCT02203773), were presented at the 2020 American Society for Hematology Annual Meeting & Exposition, and provided further evidence of an effective treatment for this patient cohort, many of whom are ineligible for intensive chemotherapy due to existing comorbidities or age.

In an interview with CancerNetwork®, Dan Pollyea, MD, MS, of the University of Colorado Cancer Center, discussed how these mutations were originally discovered.

Transcript:

We have only known about the presence of IDH in AML for about the last 10 years. It’s really a fascinating story. A little over 10 years ago, the first patient with cancer had whole genome sequencing performed. That patient happened to [have AML], and that patient happened to have an IDH1 mutation. That was published in the New England Journal of Medicine. We’ve since gone back and looked and done targeted resequencing to see what the incidence of IDH1 and IDH2 mutations are in AML; it’s upwards of 20% of patients who have these mutations, which we didn’t even know about them before. It’s really fascinating story. Add to that the fact that these are targetable mutations on their own and that there are 2 therapies that are specifically FDA approved for use in the relapse setting for patients with IDH1 and IDH2 mutations. There’s just been a lot of excitement around this in general.

Reference:

Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058-66. doi: 10.1056/NEJMoa0903840

Recent Videos
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Related Content
Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Defining the Role of Immune Therapy in Multiple Myeloma

Roman Fabbricatore
August 9th 2025
Article

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 1st 2025
Article

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.

Tarlatamab and DLL3 May Open New Opportunities in SCLC Management

Russ Conroy
August 1st 2025
Article

The field is just beginning to open the door for cellular therapy in lung cancer and other solid tumors, according to Daniel R. Carrizosa, MD, MS, FACP.